stockrow
Friday 6 November 2026
Export CLLS’s income statement to Excel — free account
Cellectis S.A.
CLLS Healthcare Biotechnology
Cellectis S.A.’s revenue for fiscal 2025 (year ended December 2025) was $79.6 million, up 61.7% from fiscal 2024.
- Revenue
- −62.1%
- EPS
- +8.33%
- Free cash flow
- −37.0%
- Total debt
- −0.54%
Quarter to June 2026, against a year earlier
1.07
0.04
+3.88%
Follow CLLS
Alert me
Cellectis S.A. (CLLS) P/E ratio
Cellectis S.A. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 183× (May 2015) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 42 more quarters | Free account |
Against its own ten years
Low 0.0×
High 183×
Ten-year median
0.0×
Current reading's percentile
98
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| MNOV MediciNova, Inc. compare | n/m |
| NRXS Neuraxis, Inc. compare | n/m |
| RANI Rani Therapeutics Holdings, Inc. compare | n/m |
| OKYO OKYO Pharma Limited Sponsored ADR compare | n/m |
| CLLS Cellectis S.A. | n/m |
| TNXP Tonix Pharmaceuticals Holding Corp. compare | n/m |
| TNYA Tenaya Therapeutics, Inc. compare | n/m |
| ATRA Atara Biotherapeutics, Inc. compare | n/m |
| TLSA Tiziana Life Sciences Ltd compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)